Trial Profile

A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucidinostat (Primary) ; Exemestane
Indications Advanced breast cancer
Focus Pharmacodynamics; Pharmacokinetics; Registrational; Therapeutic Use
Acronyms ACE
Sponsors Chipscreen Biosciences

Most Recent Events

10 Jan 2022 Status changed from active, no longer recruiting to completed.
17 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Apr 2021.
05 Aug 2020 Planned End Date changed from 1 Jul 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com